
Solabegron
CAS No. 252920-94-8
Solabegron ( GW 427353 )
产品货号. M24143 CAS No. 252920-94-8
Solabegron 是 β3-肾上腺素能受体的选择性激动剂,刺激表达人 β3-AR 的中国仓鼠卵巢细胞中 cAMP 的积累(EC50 :22 nM)。它用于治疗膀胱过度活动症和肠易激综合症。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥2252 | 有现货 |
![]() ![]() |
10MG | ¥3686 | 有现货 |
![]() ![]() |
25MG | ¥6707 | 有现货 |
![]() ![]() |
50MG | ¥9072 | 有现货 |
![]() ![]() |
100MG | ¥12069 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Solabegron
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Solabegron 是 β3-肾上腺素能受体的选择性激动剂,刺激表达人 β3-AR 的中国仓鼠卵巢细胞中 cAMP 的积累(EC50 :22 nM)。它用于治疗膀胱过度活动症和肠易激综合症。
-
产品描述Solabegron is a selective agonist of β3-adrenergic receptor, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR(EC50 : 22 nM). It is used for treatment of overactive bladder and irritable bowel syndrome. (In Vivo):Solabegron (GW427353) at 3 mg/kg i.v. evokes an increase in micturition volume threshold that prevented the acetic acid-evoked decreases in dogs. The low dose (1 mg/kg) shows no significant activity.
-
体外实验——
-
体内实验Solabegron (GW427353) at 3 mg/kg i.v. evokes an increase in micturition volume threshold that prevented the acetic acid-evoked decreases in dogs. The low dose (1 mg/kg) shows no significant activity. Animal Model:Adult female beagle dogs (6-10 kg).Dosage:1, 3 mg/kg.Administration:I.V. once.Result:Dosage of 3 mg/kg evoked an increase in micturition volume threshold.
-
同义词GW 427353
-
通路Apoptosis
-
靶点Adenosine Receptor
-
受体β3-adrenergic receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number252920-94-8
-
分子量410.89
-
分子式C23H23ClN2O3
-
纯度>98% (HPLC)
-
溶解度DMSO:250 mg/mL (608.44 mM; Need ultrasonic)
-
SMILESC1=CC(=CC(=C1)C(=O)O)C2=CC(=CC=C2)NCCNC[C@@H](C3=CC(=CC=C3)Cl)O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Hicks A, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007 Oct;323(1):202-9.